• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

J Virol 2014 Jun;88(11):6019-30

Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model.

Price GE, Lo CY, Misplon JA, Epstein SL

Abstract

Pandemic influenza is a major public health concern, but conventional strain-matched vaccines are unavailable early in a pandemic. Candidate "universal" vaccines targeting viral antigens nucleoprotein (NP) and matrix 2 (M2), which are conserved among all influenza A virus strains and subtypes, could be manufactured in advance for use at the onset of a pandemic. These vaccines do not prevent infection, but can reduce disease severity, deaths, and virus titers in the respiratory tract. We hypothesized that such immunization may reduce virus transmission from vaccinated, infected animals. To investigate this hypothesis, we studied mouse models for direct contact and airborne transmission of H1N1 and H3N2 influenza viruses. We established conditions under which virus transmission occurs, and showed that transmission efficiency is determined in part at the level of host susceptibility to infection. Our findings indicate that virus transmission between mice has both airborne and direct contact components. Finally, we demonstrated that immunization with recombinant adenovirus vectors expressing NP and M2 significantly reduced transmission of virus to co-housed, unimmunized mice in comparison to controls. These findings have broad implications for the impact of conserved antigen vaccines, not only in protecting the vaccinated individual but also in protecting others by limiting influenza virus transmission and potentially reducing the size of epidemics. IMPORTANCE: Using a mouse model of influenza A virus transmission, we demonstrate that a candidate "universal" influenza vaccine both protects vaccinated animals from lethal infection and reduces transmission of virus from vaccinated to non-vaccinated mice. This vaccine induces immunity against proteins conserved between all known influenza A virus strains and subtypes, so it could be used early in a pandemic before conventional strain-matched vaccines are available and could potentially reduce spread of infection in the community.


Category: Journal Article
PubMed ID: #24623430 DOI: 10.1128/JVI.03101-13
Includes FDA Authors from Scientific Area(s): Biologics
Entry Created: 2013-10-22 Entry Last Modified: 2014-06-15
Feedback
-
-